Results 141 to 150 of about 56,672 (288)

The role of protein arginine methyltransferases in sickle cell‐mediated neurovascular impairments in mice

British Journal of Pharmacology, EarlyView.
Background and Purpose Sickle cell disease (SCD) is a hereditary blood disorder caused by mutation of β‐globin. In SCD, haemoglobin polymerization causes red blood cells to assume a rigid sickle‐shape leading to neurovascular alterations, including development of vascular dementia – characterized by cognitive impairment and reduced cerebral perfusion ...
Julia Zaccarelli‐Magalhães, Mariana Sayuri Berto Udo, Drew James Smith, Julia Langman, Luiz Henrique Matuguma, Guilherme Nagamine Gomes, Peter Rodriguez, Ammar Husan, Quanguang Zhang, Christopher G. Kevil, Cristiane Teresinha Citadin, Hung Wen Lin   +11 more
wiley   +1 more source

RISIKO FEBRILE NON-HEMOLYTIC TRANSFUSION REACTION PADA RESIPIEN TRANSFUSI THROMBOCYTE CONCENTRATE NON-LEUKODEPLETED

, 2014
There is a high trending use of platelet transfusions for treatment and prophylaxis of bleeding in patients with hematologic disorders and malignancies.
, Trinovia Andayaningsih, , dr. Teguh Triyono, M.Kes., Sp.PK(K).   +1 more
core  

Safer Access With Fewer Transfusions: Revisiting Platelet Thresholds in Pediatric Central Venous Catheterization

European Journal of Haematology, EarlyView.
ABSTRACT Background Central venous catheters (CVCs) are essential in pediatric hematology‐oncology, for the administration of chemotherapy and supportive therapy. Thrombocytopenia increases the risk of bleeding and current guidelines recommend prophylactic platelet transfusions below 40–50 × 109/L, though evidence is limited and transfusions entail ...
Alessandro Raffaele, Carlo Maria Ferlini, Marta Gazzaneo, Piero Giovanni Romano, Bilge Rol, Francesco Delle Cave, Stella Boghen, Tommaso Mina, Marco Zecca   +8 more
wiley   +1 more source

A Survey of Acute Transfusion Reactions in Thalassemic Patients in Pakistan: A Single Centre Experience

Background: Blood transfusion reactions are characterized as adverse reactions linked to whole blood or any of its constituent parts, encompassing a spectrum of severity levels, from minor to potentially life-threatening.
Sajid Ullah Khan, Muhammad Iqbal, Jamshid Ullah, Muhammad Rabnawaz, Muhammad Umair, Sarzamin Khan   +5 more
core   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Outcomes of dengue infection in adults with underlying haematological diseases in Brazil during 2024 and 2025

British Journal of Haematology, EarlyView.
K. Tozatto‐Maio, V. Weihermann, C. W. Erthal, M. W. Araújo, C. R. Gomes, K. Caciola, L. Otuyama, J. Gasparini, H. R. Higashino, S. F. Costa, A. N. Duarte‐Neto, F. S. Seguro, P. R. Villaça, E. D. R. P. Velloso, S. F. M. Gualandro, Y. Nukui, V. Rocha   +16 more
wiley   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

Anti‐HPA‐1a IgG3 subclass antibodies induce strong platelet phagocytosis

British Journal of Haematology, EarlyView.
Silke Schmidt, Xiuzhang Xu, Gabriela Michel, Hartmut Kroll, Gregor Bein, Sentot Santoso   +5 more
wiley   +1 more source

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Small Bowel Lesions and Bleeding Risk in Hemodialysis Patients: A Narrative Review

Hemodialysis International, EarlyView.
ABSTRACT Background Gastrointestinal bleeding is very common among hemodialysis patients. This high bleeding risk is caused by uremic platelet dysfunction, vascular fragility, intradialytic hemodynamic instability, and widespread antithrombotic therapy.
Andreas Smyrlis, Konstantia Kantartzi, Konstantinos Mimidis, Stylianos Panagoutsos   +3 more
wiley   +1 more source